ライフサイエンスコーパス: coagulation factor

1 tatic components (platelets, fibrinogen, and coagulation factors).

2 ) results in decreased plasma levels of this coagulation factor.

3 C as well as a direct inhibitor of multiple coagulation factors.

4 assessment, including an extensive panel of coagulation factors.

5 ions with histology were found for the other coagulation factors.

6 , including mast cell tryptase and activated coagulation factors.

7 arked angiogenesis with elevation in several coagulation factors.

8 to sustain gamma-carboxylation of many blood coagulation factors.

9 bits serine proteases, including trypsin and coagulation factors.

10 pendence of the INR on the concentrations of coagulation factors.

11 ulation involves activation of platelets and coagulation factors.

12 s virus binding to vitamin K-dependent blood coagulation factors.

13 oration of a fibrin-rich network produced by coagulation factors.

14 attributed to activation and consumption of coagulation factors.

15 to occur without significant consumption of coagulation factors.

16 the catalytic surface for the activation of coagulation factors.

17 a progestin, without increasing the level of coagulation factors.

18 and can regulate clearance of platelets and coagulation factors.

19 eceptors, endothelial matrix components, and coagulation factors.

20 vation of function for a number of zebrafish coagulation factors.

21 ) may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or function

22 H may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or mutation

23 390-396A) mice appeared to be independent of coagulation factor 13 (FXIII) transglutaminase, as ANIT

24 A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 wer

25 can substitute for proline in the context of coagulation factor 9 EGF repeat for O-glucose transfer,

26 Recipients of continuous coagulation factor administration experienced either sta

27 Here we report that thrombin, a key coagulation factor and inflammatory mediator, cleaves HM

28 y expressing 2 reporter proteins (a chimeric coagulation factor and MGP) in HEK293 cells.

29 d through genome-wide association studies of coagulation factors and fibrin structure/function in hea

30 should be given for documented deficiency of coagulation factors and in the presence of active bleedi

31 Plasma levels of all coagulation factors and of the main coagulation inhibito

32 ombin activator, trypsin-like enzymes, blood coagulation factors and prophenoloxidase cascade activat

33 e pharmacokinetic profile of the substituted coagulation factor, and most recently includes novel pro

34 t information on environmental risk factors, coagulation factors, and genetic determinants in patient

35 ic and environmental risk factors, levels of coagulation factors, and other biomarkers for the occurr

36 ce for production of pig proteins, including coagulation factors; and (3) these appeared to function

37 ress markers, as well as increased levels of coagulation factors, antedated the loss of insulin secre

38 Genetic variants in coagulation factors are associated with myocardial infar

39 In the tumor microenvironment, serum coagulation factors are readily extravasated and therefo

40 the increase in PAI-1 levels, whereas other coagulation factors are unaltered.

41 All coagulation screening tests, coagulation factor assays, and platelet function test re

42 Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be bia

43 aved by matrix metalloproteinases or various coagulation factors but was efficiently cleaved by plasm

44 g of Ad to platelets and vitamin K-dependent coagulation factors, but we found that neither of these

45 duce the total amount of administered plasma coagulation factors by 10%.

46 adhesive modules including a common Limulus coagulation factor C domain also found in two additional

47 deletion mutation have been reported in the coagulation factor C homology (COCH) gene, causing the a

48 Mutations in COCH (coagulation factor C homology) are etiologic for the lat

49 Mutations in the COCH (coagulation factor C homology) gene have been attributed

50 Emerging evidence has shown that coagulation factors can directly mediate cancer-associat

51 's GGCX D153G mutant significantly decreased coagulation factor carboxylation and abolished MGP carbo

52 in K concentrations can restore up to 60% of coagulation factor carboxylation but do not ameliorate M

53 he hemostatic system as being regulated by a coagulation factor cascade coupled with platelet activat

54 proteins were clusterin (apoJ), PLTP itself, coagulation factors, complement factors, and apoA-I.

55 tration of platelet concentrates, plasma, or coagulation factor concentrates should be considered.

56 ction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged saf

57 the hypothesis that thrombin, a blood-borne coagulation factor, contributes to neurovascular injury

58 r XI deficiency is one of the rare inherited coagulation factor deficiencies.

59 e clinical tests commonly used to screen for coagulation-factor deficiencies.

60 N1-MCFD2 (lectin, mannose binding 1/multiple coagulation factor deficiency protein 2) cargo receptor

61 annose-binding protein 1) or MCFD2 (multiple coagulation factor deficiency protein 2), which encode t

62 ered in association with vitamin K-dependent coagulation factor deficiency, an autosomal recessive di

63 aneous features in association with multiple coagulation factor deficiency, an autosomal recessive di

64 stic features of PXE and vitamin K-dependent coagulation factor deficiency.

65 Vitamin K-dependent coagulation factors deficiency is a bleeding disorder ma

66 In coagulation factor-depleted mice hFX also had enhanced a

67 Warfarin pretreatment, to deplete coagulation factors, did not improve tumor uptake signif

68 s study aimed to determine whether levels of coagulation factors differ between patients with neuroim

69 use of the relative infrequency of inherited coagulation factor disorders and the availability of saf

70 p domains b1 and b2, which share homology to coagulation factor domains.

71 ase inhibitor (ZPI) is a serpin inhibitor of coagulation factor (F) Xa dependent on protein Z, Ca2+,

72 Recently, we demonstrated that coagulation factor (F)X directly binds adenovirus leadin

73 vation of AT towards efficient inhibition of coagulation factors (f) IXa and Xa.

74 activated protein C (APC), which inactivates coagulation factors (F) Va and VIIIa.

75 antibodies and mitigate the binding of blood coagulation factor (Factor X) in vitro.

76 Some recombinant vitamin K-dependent blood coagulation factors (factors VII, IX, and protein C) hav

77 Here we show that the coagulation factor fibrinogen activates the bone morphog

78 ice to directly test the hypothesis that the coagulation factor fibrinogen contributes to colitis-ass

79 effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotr

80 that should be implemented to make available coagulation factors for replacement therapy in developin

81 -income countries, the large availability of coagulation factors for replacement therapy of patients

82 The administration of coagulation factors (fresh frozen plasma, prothrombin co

83 o hemophilic mice of cholera toxin B subunit-coagulation factor fusion proteins expressed in chloropl

84 Although both coagulation factors FVII and FX bind the hexon protein o

85 from its distinct role in blood coagulation, coagulation factor FVIIa enhances aggressive behaviors o

86 models of hemostasis, we show that a variant coagulation factor, FXa(I16L), rapidly restores hemostas

87 r (alpha2-PI1-8) that is a substrate for the coagulation factor fXIIIa, to allow its covalent cross-l

88 Thrombin, a serine protease, is a well-known coagulation factor generated during vascular injury and

89 reeze-dried blood, and recombinant activated coagulation factor has attracted focused interest.

90 The growing availability of synthetic coagulation factors has (at least in the western hemisph

91 Selective inhibitors of specific coagulation factors have the potential to be more effect

92 the 5' promoter region of factor VII (F7), a coagulation factor, have been shown to affect its transc

93 After LXT, baboons received no coagulation factors (historical control, n = 1), bolus a

94 terval: 1.42, 2.54; 23 studies, I(2) = 29%), coagulation factor II (thrombin) gene (F2) mutation G202

95 osine-guanine dinucleotide (CpG) site within coagulation factor II (thrombin) receptor-like 3 (F2RL3)

96 ation levels (M values) of cg03636183 in the coagulation factor II (thrombin) receptor-like 3 gene (F

97 ing the thrombin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5

98 w that the G protein-coupled receptor (GPCR) coagulation factor II receptor-like 1 (F2rl1, previously

99 tients were randomized to 4F-PCC (containing coagulation factors II, VII, IX, and X and proteins C an

100 caused by an inability to synthesize active coagulation factors II, VII, IX, and X, although there i

101 nes related to coagulation and inflammation: coagulation factor III (F3), intercellular adhesion mole

102 P=6.4x10(-52)) was 46.0 kb upstream from F3, coagulation factor III (tissue factor).

103 ating the role of cell-surface receptors for coagulation factors in mouse endotoxemia, we found that

104 Elevation of multiple coagulation factors in Mrc1(-/-)Asgr2(-/-) mice may acco

105 models have implicated an integral role for coagulation factors in neuroinflammatory diseases such a

106 ravascular sites, the expression and role of coagulation factors in NP remain unclear.

107 s study was to investigate the expression of coagulation factors in patients with chronic rhinosinusi

108 udy, we determined antigenic levels of these coagulation factors in primarily pre-event blood samples

109 carboxylase necessary for activation of both coagulation factors in the liver and matrix gla protein,

110 Besides autoimmune mechanisms, coagulation factors, in particular tissue factor and thr

111 anticoagulant warfarin, which depletes other coagulation factors including thrombin, there is a reduc

112 oticeably absent in recipients of continuous coagulation factor infusions compared with the historica

113 In patients who died, coagulation factors involved in the common pathway were

114 se of plasma, platelets, cryoprecipitate and coagulation factor isolates, decrease blood loss in trau

115 g disorder hemophilia B [deficiency in blood coagulation factor IX (F.IX)] by gene replacement therap

116 at antigenic epitopes derived from an ARF in coagulation factor IX (F9) cDNA can induce CTL reactivit

117 n particular, we target a promoterless human coagulation factor IX (F9) gene to the liver-expressed m

118 d efficient induction of immune tolerance to coagulation factor IX (FIX) by direct intramuscular inje

119 emonstrated induction of immune tolerance to coagulation factor IX (FIX) by hepatic adeno-associated

120 d mice with combined deficiencies of Plg and coagulation factor IX (fIX) or XI (fXI) to determine the

121 safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which,

122 A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP)

123 onsidering the enzymatic domain of activated coagulation factor IX (FIXa) is homologous to those of t

124 In hemophilia B (coagulation factor IX [F.IX] deficiency), lack of endoge

125 haemophilia B (</=2 IU/dL [</=2%] endogenous coagulation factor IX [FIX] activity).

126 xicity and promote the delivery of the human coagulation factor IX and alpha-galactosidase genes into

127 We demonstrated that coagulation factor IX and complement component C4-bindin

128 Oral delivery of coagulation factor IX fused with cholera toxin beta-subu

129 are the result of missense mutations in the coagulation factor IX gene and defective circulating fac

130 gene on the X chromosome that encodes blood coagulation factor IX, and is predicted to alter RNA spl

131 d expressing a model therapeutic gene, human coagulation Factor IX, in HEK293T cells.

132 calin from Rhodnius prolixus that binds with coagulation factors IX (fIX) and IXa (fIXa).

133 We studied associations of coagulation factors IX through XIII with risk of future

134 of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary

135 pulation of PAR-1-stimulated platelets binds coagulation factor IXa, since confirmed by other laborat

136 During blood coagulation, factor IXa (FIXa) activates factor X (FX) r

137 complex concentrates; the variability in the coagulation factor levels and contents of prothrombin co

138 The changes in coagulation factor levels matched the changes in activit

139 Our study demonstrates that coagulation factors may be key mediators in neuroinflamm

140 ypsin but, in contrast to thrombin and other coagulation factors, Na(+) did not stimulate the activit

141 agulants effectively inhibit the activity of coagulation factors of the extrinsic and common pathway

142 geneity in the surface distribution of major coagulation factors on the surface of procoagulant plate

143 Spatial distribution of blood coagulation factors on the surface of procoagulant plate

144 d include deficiency of hepatic synthesis of coagulation factors owing to hepatocellular necrosis, cy

145 Although coagulation factors play a role in host defense for "liv

146 The genes encoding the coagulation factor proteins were among the first human g

147 The coagulation factor prothrombin has a complex spatial org

148 acids connects kringle-1 to kringle-2 in the coagulation factor prothrombin.

149 cal side effects, while use of fibrinogen or coagulation factors provides only partial mechanisms for

150 Coagulation factor replacement therapy for the X-linked

151 le we concur with the concept of pre-emptive coagulation factor replacement, and initially suggested

152 tion tests are not sensitive to increases in coagulation factors resulting from plasma transfusion.

153 A subsequent search for specified coagulation factors revealed a lamprey system with a sma

154 first drugs designed to inhibit platelets or coagulation factors, such as the antiplatelet clopidogre

155 cell surface receptors, growth factors, and coagulation factors to perform its key roles in fibrin c

156 Binding of coagulation factors to phosphatidylserine (PS)-exposing

157 despite high-affinity binding of both these coagulation factors to the virus.

158 Affected individuals have normal levels of coagulation factor V (FV) activity, but demonstrate inhi

159 Coagulation factor V (FV) circulates as an inactive proc

160 c donor splice site in a patient with severe coagulation factor V (FV) deficiency and life-threatenin

161 ion, which endocytoses fluorescently labeled coagulation factor V (FV) from the media into alpha-gran

162 Activation of blood coagulation factor V (FV) is a key reaction of hemostasi

163 binase assembly by directly interacting with coagulation factor V (FV), which has been activated by F

164 ed that Gal8 may also interact with platelet coagulation factor V (FV).

165 man genetic disorder, combined deficiency of coagulation factor V and factor VIII.

166 Blood coagulation factor V circulates as a procofactor with li

167 ed a higher risk of severe preeclampsia with coagulation factor V gene (proaccelerin, labile factor)

168 of the method to a tryptic digest of bovine coagulation factor V resulted in identification of sulfa

169 ins of intermediate abundance were selected, coagulation factor V, adiponectin, C-reactive protein (C

170 eptides were 17.0, 25.4, 24.2, and 14.0% for coagulation factor V, adiponectin, CRP, and thyroxine bi

171 ing) were 9.2, 110, 120, and 246 pmol/mL for coagulation factor V, adiponectin, CRP, and thyroxine bi

172 P=2.4x10(-14)) was 79.7 kb downstream of F5, coagulation factor V.

173 collapse; antibody (YW107.4.87) binds to the coagulation factor V/VIII domains (b1b2) of NRP1 and blo

174 The C domains of coagulation factors V (FV) and VIII (FVIII) are structur

175 protein 2) cargo receptor complex transports coagulation factors V (FV) and VIII (FVIII) from the end

176 s soluble coreceptor MCFD2, LMAN1 transports coagulation factors V (FV) and VIII (FVIII).

177 -derived prothrombin activator homologous to coagulation factors V (FV) and Xa (FXa).

178 a type II (CDAII) and combined deficiency of coagulation factors V and VIII (F5F8D) are the 2 known h

179 lopathy characterized by inactivation of the coagulation factors V and VIII and a derepression of the

180 The discoidin C2 domains of coagulation factors V and VIII are known to interact wit

181 MAD4, INPP5D, and IRAK3; and a disruption of coagulation factors V and VIII.

182 The activation of coagulation factors V and X by Russell's viper venom (RV

183 h tracks with reduced plasma levels of blood coagulation factors V, VII, VIII, IX, X, and XII.

184 ies did not involve proteolysis of activated coagulation factors Va and VIIIa.

185 Expression of the human coagulation factor VII (FVII) gene by hepatoma cells was

186 Fibrinogen, coagulation factor VII (FVII), and factor VIII (FVIII) a

187 tamic-acid-rich domain; GLA domain) of human coagulation factor VII as a test model.

188 carboxyglutamic acid domains of procoagulant coagulation factors VII (FVII) and X (FX).

189 Plasma levels of coagulation factors VII (FVII), VIII (FVIII), and von Wi

190 Here we demonstrate that coagulation factor VIIa (FVIIa) elicits TF cytoplasmic d

191 absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) predominantly exists in

192 The complex of coagulation factor VIIa (FVIIa), a trypsin-like serine p

193 inistration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999, for

194 agulation factor X by tissue factor (TF) and coagulation factor VIIa (VIIa) on a phospholipid surface

195 On complex formation with its ligand, coagulation factor VIIa, TF influences protease-activate

196 itiator of the coagulation cascade, mediates coagulation factor VIIa-dependent activation of protease

197 We previously demonstrated that coagulation factor VIII (FVIII) accelerates proteolytic

198 and at physiological pH and ionic strength, coagulation factor VIII (FVIII) accelerates, by a factor

199 philia A and B are caused by deficiencies in coagulation factor VIII (FVIII) and factor IX, respectiv

200 Complex formation between coagulation factor VIII (FVIII) and von Willebrand facto

201 The uptake and processing of blood coagulation factor VIII (FVIII) by antigen-presenting ce

202 Human and porcine coagulation factor VIII (fVIII) display a biosynthetic e

203 DLR) was shown to mediate clearance of blood coagulation factor VIII (FVIII) from the circulation.

204 Blood coagulation factor VIII (fVIII) is activated by thrombin

205 neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic

206 Regulation of the coagulation factor VIII (fVIII) level in circulation inv

207 Development of neutralizing Abs to blood coagulation factor VIII (FVIII) provides a major complic

208 The cellular source of coagulation factor VIII (FVIII) remains controversial.

209 bleeding disorder caused by a deficiency in coagulation factor VIII (fVIII) that affects 1 in 5,000

210 Hemophilia A, a deficiency of functional coagulation factor VIII (FVIII), is treated via protein

211 m and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from prot

212 We have analyzed expression of coagulation factor VIII (FVIII), the protein deficient i

213 nts in the missing secreted protein product, coagulation factor VIII (FVIII), would result in substan

214 development of inhibitor antibodies against coagulation factor VIII (fVIII).

215 ievement of sustained, therapeutic levels of coagulation factor VIII (fVIII).

216 caused by the lack or abnormality of plasma coagulation factor VIII (FVIII).

217 ed bleeding disorder caused by deficiency of coagulation factor VIII (FVIII).

218 shares homology with the C2 domains of blood coagulation factor VIII and factor V.

219 Using available genomic sequence data on coagulation factor VIII and predictive models of molecul

220 Using coagulation factor VIII as a model ligand, we now study

221 n immunodeficiency virus type 1 antigens and coagulation factor VIII captured on the cantilever in th

222 halomyelitis, and antibody responses against coagulation factor VIII in hemophilia A mice, even in an

223 ients of nonleukoreduced red blood cells and coagulation factor VIII manufactured from blood of Unite

224 cular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a l

225 function, including synthesis and release of coagulation factor VIII, demonstrated that transplanted

226 23/26del) which cannot bind platelets, blood coagulation factor VIII, or collagen, causing VWD throug

227 rs of the 18 tested (interleukin-6, d-dimer, coagulation factor VIII, von Willebrand factor, and homo

228 s also a key determinant in the clearance of coagulation factor VIII.

229 Deficiency of blood coagulation Factors VIII, IX, or XI is associated with h

230 Production of several pig coagulation factors was confirmed.

231 Assessed coagulation factors were higher in the 4F-PCC group than

232 In four baboons, coagulation factors were measured.

233 s can bind several vitamin K-dependent blood coagulation factors, which contributes to virus sequestr

234 velopment has focused on inhibiting specific coagulation factors, with those targeting thrombin and f

235 species C adenovirus (HAdv) interaction with coagulation factor X (FX) and introduced a mutation that

236 Coagulation factor X (FX) binding to HAdV-5 mediates liv

237 Recently, we demonstrated that coagulation factor X (FX) binds to Ad5-hexon protein at

238 Once in the bloodstream, coagulation factor X (FX) has a pivotal role in determin

239 studies have demonstrated the importance of coagulation factor X (FX) in adenovirus (Ad) serotype 5-

240 tocyte transduction is mediated by the hexon-coagulation factor X (FX) interaction.

241 s classical role in the coagulation cascade, coagulation factor X (FX) is involved in several major b

242 Serum coagulation factor X (FX) is proposed to play a major ro

243 major Ad5 capsid protein, hexon, binds human coagulation factor X (FX) with an affinity of 229 pM.

244 Adenovirus type 5 (Ad5) specifically binds coagulation factor X (FX), and FX is normally essential

245 r class A member I (SR-AI) as a receptor for coagulation factor X (FX), mediating the formation of an

246 he particles with plasma proteins, including coagulation factor X (FX), which binds specifically to t

247 n between the capsid hexon protein and blood coagulation factor X (FX), whilst penton-alpha(v)integri

248 Ad5 transduction requires blood coagulation factor X (FX); FX binds to the Ad5 capsid he

249 Considering that activated coagulation factor X (FXa) is homologous to thrombin in

250 thrombin, and 4 of 10 bound to the activated coagulation factor X (FXa).

251 ymatic domains of thrombin and the activated coagulation factor X (FXa).

252 virions formed unstable complexes with blood coagulation factor X and, because of that, transduced th

253 The activation of coagulation factor X by tissue factor (TF) and coagulati

254 Down syndrome critical region 1, or hagfish coagulation factor X genes.

255 in the present study, we show that activated coagulation factors X (FXa) or VII (FVIIa) directly affe

256 o using a conformationally pliant variant of coagulation factor Xa (FXa(I16L)) rendered partially ina

257 nstrate synergistic interactions between the coagulation factor Xa (fXa) and the proinflammatory cyto

258 Inhibitors of coagulation factor Xa (fXa) have emerged as a new class

259 Direct inhibitors of coagulation factor Xa (FXa) or thrombin are promising or

260 or to dramatically enhance the inhibition of coagulation factor Xa by the serpin, protein Z-dependent

261 c activation of the protease domain of human coagulation factor Xa into a bacterial trypsin.

262 in Z (PZ), to regulate the function of blood coagulation factor Xa on membrane surfaces.

263 otease inhibitor, enhances the inhibition of coagulation factor Xa, and protein Z-dependent protease

264 s in the 170, 186, and 220 loops to those of coagulation factor Xa.

265 s as a cofactor-dependent regulator of blood coagulation factors Xa (FXa) and XIa.

266 s as a cofactor-dependent regulator of blood coagulation factors Xa and XIa.

267 Coagulation factor XI (FXI) has become increasingly inte

268 Coagulation factor XI (FXI) is a covalent homodimer cons

269 Activation of coagulation factor XI (FXI) may play a role in hemostasi

270 Coagulation factor XI (FXI) plays an important part in b

271 antisense oligonucleotides (ASOs) targeting coagulation factor XI (FXI), a member of the intrinsic c

272 Since the mechanism of coagulation factor XI (FXI)-dependent thrombus growth re

273 In the intrinsic pathway of blood coagulation factor XIa (FXIa) activates factor IX (FIX)

274 To select residues in coagulation factor XIa (FXIa) potentially important for

275 Human coagulation factor XIa (FXIa), a serine protease activat

276 activity, we replaced it with Ala or Val in coagulation factor XIa (FXIa).

277 ependent fashion, but also directly inhibits coagulation factor XIa.

278 t2a, resides downstream of the gene encoding coagulation factor XII (f12) and was inadvertently modif

279 Inhibition of coagulation factor XII (FXII) activity represents an att

280 For example, mice deficient in coagulation factor XII (fXII) are protected from arteria

281 partial thromboplastin time measurement for coagulation factor XII (FXII).

282 Coagulation factor XII (FXII, Hageman factor, EC = 3.4.2

283 aused by mutation in the C1 inhibitor or the coagulation Factor XII gene.

284 Coagulation factor XII is involved in thrombus formation

285 In addition, PK can activate coagulation factor XII, the origin of the intrinsic coag

286 creased thrombus formation and activation of coagulation factor XII.

287 activity of platelets with the activation of coagulation factor XII.

288 cofactor activity in serum was dependent on coagulation factor XIIa, a serine protease known to indu

289 Coagulation factor XIII (FXIII) is a heterotetramer cons

290 Plasma coagulation factor XIII (FXIII) is a transglutaminase th

291 Coagulation factor XIII (FXIII) is a transglutaminase wi

292 Coagulation Factor XIII (FXIII) plays an important role

293 The activation and regulation of coagulation Factor XIII (FXIII) protein has been the sub

294 Activated coagulation factor XIII (FXIIIa) cross-links the gamma-c

295 ansamidation by both TG2 and activated blood coagulation factor XIII (FXIIIa).

296 Coagulation factor XIII-A has a crucial role in thrombus

297 of several proteins, including kindlin-3 and coagulation factor XIII-A.

298 Coagulation factor XIIIa (FXIIIa) is a transglutaminase

299 eover, we observed that the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most ab

300 ve shown that FnbA serves as a substrate for coagulation factor XIIIa and undergoes covalent cross-li